Hospital
Munson Medical Center
Munson Medical Center was paid $44.13M by Medicaid between Jan 2018 and Dec 2024, across 504 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 13% of everything it billed.
33Billing provider infoMUNSON MEDICAL CENTER
TRAVERSE CITY, MI 49684
TRAVERSE CITY, MI 49684
33aNPI1952307852assigned 06/24/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$44.13M
24GClaims1,622,966
24DCodes billed504
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#25 of 86
Median peer was paid$21.55M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 256,683 | $7.11M | |
| 2019 | 249,993 | $6.69M | |
| 2020 | 210,766 | $5.52M | |
| 2021 | 248,235 | $6.86M | |
| 2022 | 238,644 | $6.30M | |
| 2023 | 242,113 | $6.50M | |
| 2024incomplete | 176,532 | $5.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 13% | 112,720 | 98,900 | $5.76M |
| G0378 | Hospital observation service, per hour | 10% | 7,119 | 6,801 | $4.44M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 21,778 | 20,181 | $4.42M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.0% | 24,032 | 22,730 | $3.09M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.5% | 8,030 | 7,721 | $2.45M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.1% | 16,369 | 14,666 | $1.38M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.4% | 22,835 | 15,544 | $1.04M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 11,629 | 11,185 | $822K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.9% | 3,809 | 3,792 | $819K |
| H0019 | Behavioral health; long-term residential (non-medical, non-acute care in a residential treatment program where stay is typically longer than 30 days), without room and board, per diem | 1.8% | 4,452 | 368 | $805K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.6% | 4,731 | 3,084 | $728K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 5,087 | 4,976 | $618K |
492 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 7,648 | $596K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 5,672 | $536K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 17,588 | $476K |
| 64483 | <1% | 930 | $412K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 13,766 | $387K |
| H0018 | Behavioral health; short-term residential (non-hospital residential treatment program), without room and board, per diem | <1% | 1,037 | $366K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 8,144 | $364K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,068 | $363K |
| 90837 | Psychotherapy session, about an hour | <1% | 3,201 | $358K |
| 36415 | Collection of venous blood by venipuncture | <1% | 108,552 | $339K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 494 | $338K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,519 | $321K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,260 | $292K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 8,556 | $288K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,717 | $286K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 6,593 | $281K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15,764 | $274K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 15,700 | $272K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 6,272 | $253K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,230 | $245K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 731 | $241K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 45 | $236K |
| 86900 | <1% | 8,797 | $234K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 3,006 | $231K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,338 | $231K |
| Q9992 | Injection, buprenorphine extended-release (sublocade), greater than 100 mg | <1% | 216 | $220K |
| S9976 | Lodging, per diem, not otherwise classified | <1% | 1,107 | $220K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,967 | $215K |
| 80061 | Lipid panel | <1% | 19,488 | $212K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 10,117 | $205K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,760 | $198K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 13,022 | $197K |
| Q9991 | Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg | <1% | 202 | $197K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12,055 | $187K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,862 | $186K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 2,051 | $182K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 28,474 | $181K |
| 80053 | Comprehensive metabolic panel | <1% | 46,758 | $179K |
| 76830 | Ultrasound, transvaginal | <1% | 2,967 | $168K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,731 | $163K |
| 59025 | Fetal non-stress test | <1% | 1,782 | $157K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 7,655 | $150K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 80,352 | $138K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,535 | $137K |
| 92557 | <1% | 2,376 | $134K | |
| 97162 | <1% | 2,915 | $134K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14,673 | $131K |
| 92587 | <1% | 902 | $123K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,829 | $116K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 276 | $115K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,478 | $95K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,294 | $94K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 318 | $91K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 767 | $89K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 961 | $89K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,173 | $86K |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 293 | $85K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 748 | $85K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 8,487 | $83K |
| 93971 | <1% | 1,584 | $82K | |
| 76642 | <1% | 1,976 | $78K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,154 | $77K |
| 76801 | <1% | 1,363 | $76K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,047 | $74K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 827 | $74K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 2,993 | $73K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 7,486 | $72K |
| 86850 | <1% | 11,311 | $67K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,885 | $66K |
| 77065 | Tomosynthesis, mammo | <1% | 1,515 | $63K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,435 | $61K |
| 88342 | <1% | 1,690 | $61K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,487 | $59K |
| 86780 | <1% | 7,590 | $58K | |
| 77336 | <1% | 881 | $56K | |
| 93017 | <1% | 1,269 | $56K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15,009 | $55K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 305 | $54K |
| 94726 | <1% | 1,011 | $52K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 871 | $51K |
| 72170 | <1% | 1,382 | $50K | |
| 96415 | <1% | 1,171 | $50K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 24,572 | $49K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 652 | $49K |
| 72082 | <1% | 871 | $49K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 135 | $47K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 46,126 | $45K |
| 77334 | <1% | 107 | $45K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 90 | $45K |
| 73564 | <1% | 2,357 | $45K | |
| 88307 | <1% | 1,218 | $44K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 94 | $43K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,685 | $42K |
| 96376 | <1% | 7,597 | $41K | |
| 72110 | <1% | 1,581 | $39K | |
| 82728 | <1% | 6,150 | $39K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,991 | $39K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 28 | $38K |
| 87653 | <1% | 1,969 | $37K | |
| 85027 | <1% | 19,983 | $36K | |
| 94060 | <1% | 287 | $36K | |
| C9399 | Unclassified drugs or biologicals | <1% | 755 | $36K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,328 | $35K |
| 93975 | <1% | 305 | $35K | |
| 93458 | <1% | 24 | $34K | |
| 93225 | <1% | 762 | $34K | |
| 97597 | <1% | 397 | $34K | |
| 97161 | <1% | 811 | $34K | |
| 96367 | <1% | 1,213 | $34K | |
| 93351 | <1% | 400 | $34K | |
| 77386 | <1% | 104 | $34K | |
| 76775 | <1% | 1,864 | $33K | |
| 76536 | <1% | 665 | $32K | |
| 77066 | Tomosynthesis, mammo | <1% | 555 | $32K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,018 | $30K |
| 87150 | <1% | 1,605 | $30K | |
| 95811 | <1% | 66 | $29K | |
| 92526 | <1% | 662 | $29K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,941 | $28K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 728 | $28K |
| 93296 | <1% | 1,759 | $27K | |
| 72197 | <1% | 144 | $26K | |
| 87507 | <1% | 175 | $25K | |
| 87077 | <1% | 8,408 | $25K | |
| 73630 | <1% | 2,809 | $25K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 90 | $25K |
| 64493 | <1% | 38 | $25K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 375 | $24K |
| 49083 | <1% | 51 | $24K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,949 | $23K |
| 92523 | <1% | 286 | $23K | |
| 87340 | <1% | 5,941 | $23K | |
| 86803 | <1% | 3,545 | $23K | |
| 87186 | <1% | 7,691 | $23K | |
| 82607 | <1% | 3,482 | $23K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,301 | $23K |
| 83970 | <1% | 1,221 | $22K | |
| 84439 | <1% | 5,748 | $22K | |
| 12001 | <1% | 779 | $22K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,971 | $21K |
| 73030 | <1% | 1,988 | $21K | |
| 87070 | <1% | 6,230 | $19K | |
| 84702 | <1% | 3,839 | $19K | |
| 74018 | <1% | 1,925 | $18K | |
| 72141 | <1% | 146 | $18K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,147 | $18K |
| 86762 | <1% | 3,492 | $17K | |
| 73610 | <1% | 2,298 | $17K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,408 | $17K |
| 73130 | <1% | 2,109 | $16K | |
| 81001 | <1% | 35,902 | $16K | |
| H0001 | Alcohol and/or drug assessment | <1% | 116 | $16K |
| 84403 | <1% | 1,657 | $16K | |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 185 | $16K |
| 83550 | <1% | 4,100 | $16K | |
| 77300 | <1% | 55 | $15K | |
| 96417 | <1% | 398 | $15K | |
| 52000 | <1% | 55 | $15K | |
| 83540 | <1% | 4,910 | $15K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,065 | $14K |
| 73110 | <1% | 1,741 | $14K | |
| 88304 | <1% | 1,496 | $14K | |
| 82570 | <1% | 6,067 | $14K | |
| C1769 | Guide wire | <1% | 2,754 | $13K |
| 83735 | <1% | 17,573 | $13K | |
| 52310 | <1% | 13 | $13K | |
| 76770 | <1% | 234 | $12K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 25 | $12K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 214 | $12K |
| 71271 | <1% | 230 | $12K | |
| S0280 | Medical home program, comprehensive care coordination and planning, initial plan | <1% | 84 | $12K |
| Q3014 | Telehealth originating site facility fee | <1% | 851 | $11K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 839 | $11K |
| 77080 | <1% | 196 | $11K | |
| 83880 | <1% | 2,643 | $11K | |
| 84481 | <1% | 1,377 | $11K | |
| 73502 | <1% | 959 | $10K | |
| 95819 | <1% | 89 | $10K | |
| 82043 | <1% | 3,883 | $10K | |
| 86140 | <1% | 7,349 | $10K | |
| 97166 | <1% | 231 | $10K | |
| 87634 | <1% | 761 | $10K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 498 | $10K |
| 80076 | <1% | 14,302 | $9K | |
| 70498 | <1% | 70 | $9K | |
| 82784 | <1% | 1,893 | $9K | |
| 87081 | <1% | 4,075 | $9K | |
| 87205 | <1% | 6,087 | $9K | |
| 87088 | <1% | 3,026 | $9K | |
| 90688 | <1% | 661 | $9K | |
| 86480 | <1% | 336 | $9K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,040 | $8K |
| 82950 | <1% | 3,263 | $8K | |
| 76882 | <1% | 205 | $8K | |
| 90686 | <1% | 520 | $8K | |
| 95806 | <1% | 99 | $8K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 29 | $8K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 726 | $8K |
| 85610 | <1% | 11,999 | $8K | |
| 70486 | <1% | 255 | $7K | |
| 86706 | <1% | 1,727 | $7K | |
| 72100 | <1% | 360 | $7K | |
| 82746 | <1% | 1,274 | $7K | |
| 86376 | <1% | 983 | $7K | |
| 10060 | <1% | 82 | $7K | |
| 73140 | <1% | 845 | $7K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 587 | $7K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,656 | $6K |
| 85652 | <1% | 7,579 | $6K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 113 | $6K |
| 36591 | <1% | 151 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 454 | $6K |
| 97116 | <1% | 905 | $6K | |
| 86704 | <1% | 1,029 | $6K | |
| 92567 | <1% | 3,691 | $5K | |
| 95909 | <1% | 38 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,235 | $5K |
| 84146 | <1% | 536 | $5K | |
| 74022 | <1% | 1,248 | $5K | |
| 92586 | <1% | 69 | $5K | |
| 86038 | <1% | 926 | $5K | |
| 86039 | <1% | 942 | $5K | |
| 12011 | <1% | 216 | $5K | |
| 72070 | <1% | 208 | $5K | |
| 82565 | <1% | 3,210 | $5K | |
| 88112 | <1% | 429 | $4K | |
| 82947 | <1% | 1,600 | $4K | |
| T1007 | Alcohol and/or substance abuse services, treatment plan development and/or modification | <1% | 48 | $4K |
| 83690 | <1% | 12,307 | $4K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 68 | $4K |
| 73080 | <1% | 691 | $4K | |
| 82248 | <1% | 2,489 | $4K | |
| 83001 | <1% | 464 | $4K | |
| 87529 | <1% | 296 | $4K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 41 | $4K |
| 84460 | <1% | 2,095 | $4K | |
| 84100 | <1% | 3,945 | $4K | |
| 97165 | <1% | 97 | $4K | |
| 93970 | <1% | 41 | $4K | |
| 83516 | <1% | 873 | $4K | |
| 0012A | <1% | 114 | $4K | |
| 82670 | <1% | 288 | $4K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 69 | $3K |
| 73590 | <1% | 532 | $3K | |
| 94010 | <1% | 219 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 252 | $3K |
| 76825 | <1% | 12 | $3K | |
| 81025 | <1% | 10,286 | $3K | |
| 75574 | <1% | 42 | $3K | |
| 76870 | <1% | 127 | $3K | |
| 80305 | <1% | 5,411 | $3K | |
| 84156 | <1% | 2,282 | $3K | |
| 51798 | <1% | 1,718 | $3K | |
| 87902 | <1% | 71 | $3K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 12 | $3K |
| 84550 | <1% | 1,938 | $3K | |
| 91320 | <1% | 27 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 187 | $3K |
| 0011A | <1% | 120 | $3K | |
| 93350 | <1% | 12 | $3K | |
| 87480 | <1% | 502 | $3K | |
| 87510 | <1% | 501 | $3K | |
| 86431 | <1% | 1,112 | $3K | |
| 87660 | <1% | 501 | $3K | |
| 29515 | <1% | 38 | $3K | |
| 84450 | <1% | 1,470 | $2K | |
| 86364 | <1% | 398 | $2K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 193 | $2K |
| 87210 | <1% | 1,616 | $2K | |
| 73090 | <1% | 305 | $2K | |
| 87075 | <1% | 1,294 | $2K | |
| 87807 | <1% | 681 | $2K | |
| 73560 | <1% | 245 | $2K | |
| 82150 | <1% | 2,257 | $2K | |
| 86200 | <1% | 365 | $2K | |
| 84153 | <1% | 256 | $2K | |
| 74019 | <1% | 53 | $2K | |
| 84703 | <1% | 7,154 | $2K | |
| 88300 | <1% | 199 | $2K | |
| 83874 | <1% | 1,732 | $2K | |
| 87631 | <1% | 34 | $2K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 72 | $2K |
| 87505 | <1% | 27 | $2K | |
| 93299 | <1% | 91 | $2K | |
| 82550 | <1% | 890 | $1K | |
| 72050 | <1% | 57 | $1K | |
| 87899 | <1% | 256 | $1K | |
| 85730 | <1% | 5,669 | $1K | |
| 83615 | <1% | 909 | $1K | |
| G0008 | Administration of influenza virus vaccine | <1% | 247 | $1K |
| 96523 | <1% | 65 | $1K | |
| 73221 | <1% | 12 | $1K | |
| 92651 | <1% | 17 | $1K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $1K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 36 | $1K |
| 80074 | <1% | 53 | $1K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,020 | $1K |
| 93298 | <1% | 71 | $1K | |
| 85018 | <1% | 3,707 | $1K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 18 | $1K |
| 87427 | <1% | 256 | $1K | |
| 97163 | <1% | 27 | $1K | |
| 85014 | <1% | 3,369 | $1K | |
| 90480 | <1% | 32 | $1K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 14 | $1K |
| 0001A | <1% | 29 | $1K | |
| 86800 | <1% | 152 | $1K | |
| 87046 | <1% | 255 | $1K | |
| 87536 | <1% | 39 | $1K | |
| 87045 | <1% | 256 | $997.48 | |
| 84132 | <1% | 1,288 | $967.27 | |
| 93880 | <1% | 12 | $962.36 | |
| 85379 | <1% | 2,489 | $901.90 | |
| 83002 | <1% | 106 | $861.56 | |
| 99406 | <1% | 60 | $855.80 | |
| 81596 | <1% | 31 | $802.88 | |
| 93923 | <1% | 12 | $791.21 | |
| 84520 | <1% | 611 | $785.43 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 59 | $759.56 |
| 95800 | <1% | 13 | $758.23 | |
| 12002 | <1% | 27 | $749.65 | |
| 0002A | <1% | 19 | $719.15 | |
| 70496 | <1% | 32 | $713.66 | |
| 99496 | <1% | 12 | $706.50 | |
| 86225 | <1% | 121 | $705.94 | |
| 82533 | <1% | 135 | $705.10 | |
| 92591 | <1% | 13 | $684.93 | |
| 0134A | <1% | 20 | $683.39 | |
| 87040 | <1% | 4,483 | $670.31 | |
| 86481 | <1% | 24 | $643.56 | |
| 86923 | <1% | 61 | $631.30 | |
| 72081 | <1% | 13 | $630.24 | |
| 71101 | <1% | 85 | $625.38 | |
| 82077 | <1% | 4,943 | $608.21 | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 12 | $567.81 |
| 90656 | <1% | 46 | $567.19 | |
| 29125 | <1% | 250 | $563.83 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,564 | $553.17 |
| 92610 | <1% | 13 | $550.80 | |
| 81003 | <1% | 7,730 | $529.05 | |
| 87329 | <1% | 108 | $524.82 | |
| 0064A | <1% | 20 | $511.55 | |
| 82105 | <1% | 77 | $510.11 | |
| 0124A | <1% | 24 | $504.91 | |
| 88341 | <1% | 419 | $497.20 | |
| 0071A | <1% | 14 | $492.05 | |
| 0072A | <1% | 14 | $492.05 | |
| 86308 | <1% | 348 | $491.01 | |
| 87328 | <1% | 95 | $481.24 | |
| 93226 | <1% | 731 | $451.61 | |
| 84402 | <1% | 56 | $443.78 | |
| 80164 | <1% | 81 | $378.13 | |
| 82803 | <1% | 1,449 | $360.36 | |
| 80069 | <1% | 94 | $360.03 | |
| 97602 | <1% | 13 | $344.00 | |
| 84484 | <1% | 13,768 | $323.24 | |
| 82140 | <1% | 108 | $319.15 | |
| 82962 | <1% | 18,342 | $312.49 | |
| 83993 | <1% | 27 | $294.79 | |
| 86920 | <1% | 38 | $286.00 | |
| 83605 | <1% | 5,524 | $260.27 | |
| 86901 | <1% | 8,796 | $230.27 | |
| 96402 | <1% | 13 | $227.71 | |
| 87428 | <1% | 15 | $214.50 | |
| J3490 | Unclassified drugs | <1% | 1,351 | $194.65 |
| 87147 | <1% | 100 | $188.61 | |
| 92579 | <1% | 13 | $162.30 | |
| 86235 | <1% | 25 | $160.21 | |
| 82948 | <1% | 2,189 | $143.45 | |
| 87641 | <1% | 13 | $137.06 | |
| 80178 | <1% | 58 | $133.93 | |
| 83630 | <1% | 25 | $131.40 | |
| 86709 | <1% | 24 | $127.44 | |
| 82378 | <1% | 14 | $106.80 | |
| 86708 | <1% | 26 | $87.74 | |
| 87640 | <1% | 12 | $78.32 | |
| 86618 | <1% | 12 | $76.00 | |
| 83525 | <1% | 12 | $74.80 | |
| 82330 | <1% | 40 | $71.03 | |
| 76820 | <1% | 147 | $64.84 | |
| 82977 | <1% | 29 | $63.42 | |
| 82365 | <1% | 38 | $61.20 | |
| 90715 | <1% | 1,705 | $60.30 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,981 | $57.38 |
| 80051 | <1% | 68 | $54.55 | |
| 80143 | <1% | 967 | $47.99 | |
| 82247 | <1% | 28 | $45.72 | |
| 81002 | <1% | 328 | $42.48 | |
| 84165 | <1% | 12 | $38.34 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13,642 | $37.68 |
| 80179 | <1% | 896 | $37.09 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,664 | $36.46 |
| 70360 | <1% | 12 | $31.62 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 3,091 | $23.15 |
| 80177 | <1% | 26 | $21.75 | |
| 82010 | <1% | 192 | $21.45 | |
| 85384 | <1% | 12 | $17.34 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,022 | $12.96 |
| 82075 | <1% | 575 | $11.87 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,794 | $11.66 |
| 85045 | <1% | 19 | $11.65 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,268 | $10.78 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 21,213 | $8.10 |
| J2704 | Injection, propofol, 10 mg | <1% | 10,902 | $7.15 |
| 80047 | <1% | 105 | $6.96 | |
| 84155 | <1% | 12 | $4.36 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,849 | $4.02 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 12,264 | $3.95 |
| 89050 | <1% | 49 | $2.76 | |
| 81000 | <1% | 25 | $2.05 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 10,053 | $2.01 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,403 | $0.86 |
| 90670 | <1% | 14 | $0.40 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,178 | $0.01 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 2,163 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 3,065 | $0.00 |
| 99001 | 0% | 54 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 37 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 2,929 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 1,410 | $0.00 |
| 93325 | 0% | 1,081 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 2,444 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 2,173 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 891 | $0.00 |
| C1729 | Catheter, drainage | 0% | 600 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 484 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 452 | $0.00 |
| 94729 | 0% | 963 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 2,874 | $0.00 |
| 99152 | 0% | 68 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 192 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 539 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 561 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 877 | $0.00 |
| 76942 | 0% | 38 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 12 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 116 | $0.00 |
| 77002 | 0% | 31 | $0.00 | |
| 91300 | 0% | 45 | $0.00 | |
| 88312 | 0% | 15 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 266 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 83 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 73 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 13 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 89 | $0.00 |
| 76937 | 0% | 12 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 78 | $0.00 |
| J0735 | Injection, clonidine hydrochloride, 1 mg | 0% | 45 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 260 | $0.00 |
| 84145 | 0% | 12 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 13 | $0.00 |
| 88313 | 0% | 14 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 2,952 | $0.00 |
| 93320 | 0% | 573 | $0.00 | |
| 95886 | 0% | 705 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 2,364 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 649 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 439 | $0.00 |
| A9270 | Non-covered item or service | 0% | 503 | $0.00 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 373 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 276 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 937 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 415 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 30 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 612 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 643 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 965 | $0.00 |
| 96368 | 0% | 764 | $0.00 | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | 0% | 107 | $0.00 |
| 91301 | 0% | 239 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 110 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 329 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 69 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 52 | $0.00 |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | 0% | 24 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 142 | $0.00 |
| 99156 | 0% | 13 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 132 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 42 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 44 | $0.00 |
| 64494 | 0% | 25 | $0.00 | |
| 88311 | 0% | 12 | $0.00 | |
| 74420 | 0% | 66 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 13 | $0.00 |
| 93297 | 0% | 12 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 37 | $0.00 |
| 0240U | 0% | 12 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 25 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 109 | $0.00 |
| 91307 | 0% | 36 | $0.00 | |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | 0% | 13 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLARAIA, KATHLEEN (PRESIDENT AND CEO)
Parent organizationMUNSON HEALTHCARE
| Provider | Location | Paid |
|---|---|---|
| Munson Dialysis Center | Traverse City, MI | $89K |
| Munson Medical Center | Chicago, IL | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.